• Founders
W. Daniel Hillis, Ph.D., Co-founder and Director

W. Daniel Hillis, PhD

Co-founder and Director

W. Daniel Hillis is Chairman and Chief Technology Officer of Applied Minds, a research and development company creating a range of new products and services in software, hardware, and  biotechnology.  He is Professor of Research Medicine in the Keck School of Medicine at USC and is the Widney Professor of Engineering and Medicine at USC. Previously, Hillis was VP, R&D at Walt Disney Imagineering. Hillis was co-founder of Thinking Machines Corp., a leading innovator in massive parallel supercomputers and RAID disk arrays. In addition to conceiving and designing the company’s major products, he worked closely with customers in applying parallel computers to a wide range of problems in biology, physics, finance and engineering.

David B. Agus, MD, Co-founder and Director

David B. Agus, MD

Co-founder and Director

David B. Agus received his undergraduate degree from Princeton University and his M.D. from the University of Pennsylvania. Dr. Agus then spent two years at the NIH as a Howard Hughes Medical Institute-NIH Research Scholar and did his medical internship and residency training at Johns Hopkins Hospital. Dr. Agus completed his oncology fellowship training at MSKCC where later he served as attending physician in the Department of Medical Oncology and as head of the Laboratory of Tumor Biology. He was the founder of Oncology.com, the largest cancer internet resource/community, and of Navigenics, a health care technology and wellness company. Dr. Agus recently moved to the University of Southern California to lead the Westside Cancer Center and the Center for Applied Molecular Medicine.

  • Executive Team
Peter Klemm, PhD, President/CEO

Peter Klemm, PhD


Peter serves as Chief Executive Officer of Applied Proteomics. He brings more than 20 years of leadership in the life science industry building companies and creating markets for novel high-value products. Currently he also serves as the Chairman of the Board of Pathwork Diagnostics. Previously, Peter was the CEO of Predictive Biosciences a fully integrated developer of novel molecular diagnostic cancer assays. Prior to his tenure at Predictive Biosciences, Peter was the CEO of GeneOhm Sciences, a molecular diagnostics company, which he led starting in 2002 and successfully sold to Becton Dickinson in 2006 for $255 million. Prior to Peter’s tenure at GeneOhm Sciences, he was CEO of JOMED, Inc., a Swiss-based company that develops and manufactures products for interventional cardiology, radiology and minimally invasive vascular surgery. Following JOMED’s successful initial public offering and the acquisition of Endosonics, Inc., Peter moved to the United States to integrate the companies. In advance of his time at JOMED, Peter served as senior vice president of research and development at Gruenenthal GmbH, a European pharmaceutical company. Additionally, Peter held the position of senior scientist with Aventis in their cardiovascular drug discovery unit and served as a post-doctoral fellow at the William Harvey Research Institute in London with Sir John Vane.

John E. Blume, PhD, Chief Science Offiicer

John E. Blume, PhD

Chief Science Officer

John E. Blume, PhD joined Applied Proteomics, Inc. as Chief Science Officer in September, 2008. He is a molecular biologist by training and has published research in the area of genetics and gene expression variation. In addition, he has developed an expertise for moving technologies from product development to commercialization.  Prior to joining Applied Proteomics, Dr. Blume was Senior Vice President, Product Development at Affymetrix, Inc., leading a group of over 200 for assay, software, and hardware development, bioinformatics, and product development process control. Before joining Affymetrix in 2002, Dr. Blume spent twelve years in diabetes drug discovery, first at Novartis and then at Metabolex, implementing novel molecular technologies for preclinical research and development.

Steve Martin, Chief Financial Officer

Steve R. Martin

Chief Financial Officer

Steve R. Martin joined Applied Proteomics, Inc. as Chief Financial Officer in December 2014.  He brings over 30 years of progressive experience in senior financial roles including leadership positions in publicly-traded diagnostic and pharmaceutical companies.  Prior to joining Applied Proteomics, Inc., Mr. Martin was the CFO of Apricus Biosciences, a publicly-traded pharmaceuticals company. Prior to Apricus, he was CFO and interim CEO of BakBone Software, where he led the sale of the Company to Quest Software.  Before that, Mr. Martin was senior consultant to the CEO and Acting Chief Accounting Officer for Leap Communications. Mr. Martin’s experience includes leadership roles in two diagnostics and tools companies, including as CFO of Strategene Corporation, sold to Agilent Technologies in 2007 and as Controller for Gen-Probe, now a part of Hologic. Mr. Martin began his career at Deloitte and served as Senior Audit Manager and has a B.S. in Accounting from San Diego State University.

Premal Shah, PhD, Vice President, Business Development

Premal Shah, PhD

Vice President, Business Development

Premal S. Shah, Ph.D. is Vice President of Business Development at Applied Proteomics, Inc. He is an experienced business development executive specializing in strategy, business and product development for healthcare companies. Prior to API, Dr. Shah was director of business development for Genomic Health, a leading personalized medicine company. He was responsible for leading many of the company’s strategic initiatives including partnerships and M&A activities. Previous to Genomic Health, Dr. Shah was a management consultant at Booz & Company, advising top healthcare companies in strategic matters ranging from go-to-market strategies and international expansion to M&A. Dr. Shah received his Ph.D. in molecular biophysics from the California Institute of Technology.

Bruce E. Wilcox, PhD, Vice President, Laboratory Operations

Bruce E. Wilcox, PhD

Vice President, Laboratory Operations

Bruce E. Wilcox, Ph.D., is Vice President of Lab Operations and a Founding Scientist at Applied Proteomics, Inc. He is an analytical chemist by training with expertise in mass spectrometry. Prior to API, Dr. Wilcox designed ion optics for enhanced ion transmission, built a 12-channel time of flight mass spectrometer and worked on a wide range of application-based projects, including high throughput pharmaceutical analysis, protein characterization, biomarker discovery, petrochemical analysis, and space and military projects. He joined Applied Minds, Applied Proteomic’s parent company, in 2007, and built the successful biomarker discovery platform that is used by API today.

  • Directors
James C. Blair, PhD

James C. Blair, PhD

Dr. Blair has been a Partner of Domain since its founding in 1985. Present board memberships include Applied Proteomics, Astute Medical, aTyr Pharma, Cadence Pharmaceuticals, Clovis Oncology, CoDa Therapeutics, IntegenX, Meritage Pharma, NeuroPace, and Zogenix. Dr. Blair has over 40 years experience with venture and emerging growth companies. In the course of his experience, he has been involved in the creation and successful development at the Board level of over 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Dura Pharmaceuticals, GeneOhm Sciences, Molecular Dynamics, NuVasive, Pharmion and Volcano. A former managing director of Rothschild Inc., Dr. Blair was directly involved at a senior level with Rothschild/New Court venture capital activities from 1978 to 1985. From 1969 to 1978, he was associated with F.S. Smithers and Co. and White, Weld and Co., two investment banking firms actively involved with new ventures and emerging growth companies. From 1961 to 1969, Dr. Blair was an engineering manager with RCA Corporation, during which time he received a David Sarnoff Fellowship. Dr. Blair currently serves on the Board of Directors of the Prostate Cancer Foundation, and he is on the Advisory Boards of the Department of Molecular Biology at Princeton University, the USC Stevens Institute for Innovation, and the Caltech Division of Chemistry and Chemical Engineering, and the Caltech Innovation Initiative.

Daniel Abrutyn, President

Daniel Abrutyn

Daniel Abrutyn is the President of Applied Minds, LLC, a research and development company that invents, designs and prototypes high technology products and systems. Applied Minds works on a diverse set of projects including biotechnology, database software, enterprise software, robotics, visualization systems and conceptual design. It also partners with leading corporations and the US Government by providing them with technology solutions for their most compelling opportunities or challenging problems. Since joining Applied Minds, Dan has led the formation of six new companies including Metaweb Technologies, Inc. (acquired by Google, Inc.).

Previously, Dan was the Operating Partner at BV Capital, an internet, media and communications focused venture capital fund, the CFO/COO of allbusiness.com, a small business portal, and the President of 1stUp.com, an internet service provider owned by CMGi, Inc. Dan began his career as an investment banker at Lazard Frères & Co. where he specialized in corporate finance and mergers and acquisitions. He currently serves on the board of directors of Applied Proteomics, Inc., PeoplePoint Systems, Inc. and TouchTable, Inc.

He is a graduate of the University of Pennsylvania.

Erik Holmlin, PhD

Erik Holmlin, PhD

Erik Holmlin has two decades of experience in the life science and health care industries. His expertise spans technology development and commercialization, global marketing, commercial operations, venture financing, mergers & acquisitions and intellectual property. Recently, he served as president and CEO of GenVault Corporation, a life science company bringing innovative solutions to biosample management. He merged GenVault with IntegenX, Inc. in January of 2011. He also served as an entrepreneur in residence (EIR) at Domain Associates, LLC, a leading dedicated life science venture-capital firm. Prior to these roles, Erik was chief commercial officer at Exiqon A/S, where he was responsible for global sales, marketing, and clinical affairs for two businesses: Oncology Services in a CLIA lab and Consumables Business in Life Sciences Research. In 2001 Mr. Holmlin led the formation of GeneOhm Sciences, Inc., for which, over a span of 5 years, he was director of chemistry, senior technology director, vice president of technology and business development, and vice president of marketing. At GeneOhm, he also led or participated in securing three rounds of venture financing and in the acquisition of Infectio Diagnostics, Inc., and orchestrated GeneOhm's acquisition in 2006 by Becton Dickinson. As an executive at BD, he then served as vice president of marketing and development, responsible for multiple product launches and managing more than 80 employees in three sites and two countries.

Tan Sri Lim Kok Thay

Tan Sri Lim Kok Thay

Tan Sri Lim Kok Thay is a progressive innovator and a visionary entrepreneur. He spearheads the Genting Group, one of Asia’s leading and most dynamic conglomerates with investments in biotechnology, energy, property development, leisure and gaming. KT Lim is an appointed Visiting Professor of the Institute of Biomedical Engineering, Imperial College London, and an appointed Honorary Professor of Xiamen University, China. He holds a Bachelor of Science in Civil Engineering from the University of London. He attended the Programme for Management Development at Harvard Business School in 1979. He is Chairman of the board of trustees for The Community Chest, Malaysia, an independent, non-profit organization established by the private sector to promote and support education in Malaysian communities. For his significant contributions to the leisure and travel industry, he was bestowed the national award and title of “Tan Sri” by His Majesty, the Yang DiPertuan Agong of Malaysia in June 2002. He was named “Travel Entrepreneur of the Year” by Travel Trade Gazette (TTG) Asia, “The Most Influential Person in Asian Gaming” by Inside Asian Gaming and “Asian Leader for Global Leisure and Entertainment Tourism” by Seagull Philippines Asian Leaders.